Experimental Dual-Target CAR-T therapy enters human testing for tough blood cancers
NCT ID NCT07002112
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study is testing a new gene therapy that reprograms a patient's own immune cells to attack two targets (CD19 and CD20) on cancer cells. The trial will enroll 30 adults with B-cell cancers that have come back or not responded to treatment. The main goals are to check safety, find the right dose, and see if the therapy shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CD19/CD20 dual-target CAR-T lentiviral product (a type of gene therapy that reprograms a patient's own immune cells to attack cancer cells)
What this could lead to
If successful, this could provide a new treatment option for patients with hard-to-treat B-cell cancers that have not responded to standard therapies.
What could go wrong
This is an early Phase 1 trial with only 30 participants, so safety and effectiveness are not yet proven. There is a risk of serious side effects, and the therapy may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Gobroad Boren Hospita
RECRUITINGBeijing, Beijing Municipality, 102206, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The First Affiliated Hospital of USTC west district
RECRUITINGHefei, Anhui, 230000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The First Affiliated Hospital of ZHENGZHOU University
NOT_YET_RECRUITINGZhengzhou, Henan, 450000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The First Affiliated Hospital with Nanjing Medical University
RECRUITINGNanjing, Jiangsu, 210029, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Fourth Hospital of Hebei Medical University
RECRUITINGShijiazhuang, Hebei, 050000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Union Hospital Tongji Medical College Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact